Cancer targeting using tumor suppressor genes.
Conventional cancer treatments include cytotoxic chemotherapies and radiotherapy, which result in significant collateral toxicities. The goal for future cancer treatments is to leverage improved understanding of cancer biology mechanisms and thereby develop targeted drugs that display exquisite tumor selectivity and avoid iatrogenic damage. In this review, we discuss the potential of tumor suppressor genes for development of cancer-selective drugs using the tumor suppressor p53 as an archetype.
Chada
Sunil
S
Department of Clinical Research and Development, Introgen Research Institute, Introgen Therapeutics Inc., Houston, Texas 77030, USA. s.chada@introgen.com
Menander
Kerstin B
KB
Bocangel
Dora
D
Roth
Jack A
JA
Ramesh
Rajagopal
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D014765:Viral Vaccines / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D014765:Viral Vaccines; C512972:advexin